Big things are bubbling to the surface at the life science and emerging technologies business incubator, GR Current.
The latest news on one of their tenants is about Syzygy Biotech, a company that manufactures and markets its full line of reagents used by research facilities, universities, and diagnostic labs nationwide.
The news? Welcome Empirical Bioscience and goodbye, Syzygy Biotech.
Looking to build on it’s four years of growth the firm recently changed it’s name to Empirical Bioscience, which company officials say better reflects it’s mission and positions the firm for future growth.
Secondly, and perhaps more important than the name change, is the election of Richard Leach, Ph.D., Vice President of Business Development at Complete Genomics Inc. and an expert in human genome sequencing, to its board of directors.
Dr. Leach has extensive experience within the industry. His addition to the board clearly positions the firm for a bigger role on the international stage. He views the firm as being on the brink for tremendous growth. “Empirical Bioscience designs and manufactures an assortment of high-grade molecular biology products that are used every day in labs across the nation. Because we are on the ground floor of this research and diagnostics work, we can see clearly where the biotech industry is headed. And one area that is exploding right now is genomic medicine, where we assess a person’s risk for different diseases and offer preventative treatments.”